{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:02:39Z","timestamp":1786993359359,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M710562"],"award-info":[{"award-number":["2022M710562"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["kryc-yq-2215"],"award-info":[{"award-number":["kryc-yq-2215"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Chongqing Natural Science Foundation","doi-asserted-by":"publisher","award":["CSTB2023NSCQ-MSX0176"],"award-info":[{"award-number":["CSTB2023NSCQ-MSX0176"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Chongqing Natural Science Foundation","doi-asserted-by":"publisher","award":["cstc2020jcyj-msxmX0149"],"award-info":[{"award-number":["cstc2020jcyj-msxmX0149"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001434"],"award-info":[{"award-number":["82001434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jpsychires.2025.02.044","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T11:57:59Z","timestamp":1740484679000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and safety of newer-generation antidepressants medications in Parkinson's disease with depression - A meta-analysis of randomized controllde trials"],"prefix":"10.1016","volume":"184","author":[{"given":"Fenghua","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manxue","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0451-4597","authenticated-orcid":false,"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jpsychires.2025.02.044_bib1","article-title":"Pharmacological and non-pharmacological treatments for depression in Parkinson's disease: an updated review","volume":"59","author":"Angelopoulou","year":"2023","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"Suppl. 2","key":"10.1016\/j.jpsychires.2025.02.044_bib2","first-page":"S50","article-title":"Beyond the dopaminergic System: lessons learned from levodopa resistant symptoms in Parkinson's disease","volume":"10","author":"Antonini","year":"2023","journal-title":"Movement disorders clinical practice"},{"issue":"8","key":"10.1016\/j.jpsychires.2025.02.044_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/mds.20895","article-title":"Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life","volume":"21","author":"Antonini","year":"2006","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.jpsychires.2025.02.044_bib4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/14656566.2023.2240228","article-title":"The pharmacological management of the behavioral aspects of Parkinson's disease: an update","volume":"24","author":"Campagnolo","year":"2023","journal-title":"Expet Opin. Pharmacother."},{"issue":"10128","key":"10.1016\/j.jpsychires.2025.02.044_bib5","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.jpsychires.2025.02.044_bib6","first-page":"Ed000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.jpsychires.2025.02.044_bib7","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Devos","year":"2008","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.jpsychires.2025.02.044_bib8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/jnnp.2003.027060","article-title":"Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease","volume":"75","author":"Fregni","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"11","key":"10.1016\/j.jpsychires.2025.02.044_bib9","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jpsychires.2025.02.044_bib10","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jpsychires.2025.02.044_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116833","article-title":"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease","volume":"414","author":"Iwaki","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.jpsychires.2025.02.044_bib12","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1212\/WNL.44.12.2406","article-title":"Parkinsonism exacerbated by paroxetine","volume":"44","author":"Jim\u00e9nez-Jim\u00e9nez","year":"1994","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jpsychires.2025.02.044_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5152\/AnatolJCardiol.2021.274","article-title":"High-degree atrioventricular heart block induced by pramipexole","volume":"26","author":"Kanal","year":"2022","journal-title":"Anatol. J. Cardiol."},{"issue":"6","key":"10.1016\/j.jpsychires.2025.02.044_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/gps.865","article-title":"SSRIs in the treatment of depression in Parkinson's disease","volume":"18","author":"Leentjens","year":"2003","journal-title":"Int. J. Geriatr. Psychiatr."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.02.044_bib15","first-page":"42","article-title":"The effect of fluoxetine on depressive symptom and eventreated potentials P300 in patients with Parkinson's disease","volume":"19","author":"Li","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.02.044_bib16","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jpsychires.2025.02.044_bib17","first-page":"26","article-title":"Observation on effect of prophylactic low-dose escitalopram on depressive symptoms and overall symptoms in patients with Parkinson's disease","volume":"38","author":"Lin","year":"2017","journal-title":"Journal Jinzhou Medical University"},{"issue":"10","key":"10.1016\/j.jpsychires.2025.02.044_bib18","article-title":"Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jpsychires.2025.02.044_bib19","first-page":"344","article-title":"The effects of fluoxetine on the depressive symptoms of Parkinson's disease","author":"Ma","year":"2006","journal-title":"Chinese Journal of Modern Applied Pharmacy (04)"},{"issue":"10","key":"10.1016\/j.jpsychires.2025.02.044_bib20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jpsychires.2025.02.044_bib21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.parkreldis.2014.02.025","article-title":"Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease","volume":"20","author":"Moonen","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jpsychires.2025.02.044_bib22","series-title":"Depression in Adults: Treatment and Management","year":"2022"},{"issue":"5","key":"10.1016\/j.jpsychires.2025.02.044_bib23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/M15-2570","article-title":"Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American college of physicians","volume":"164","author":"Qaseem","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.jpsychires.2025.02.044_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.7326\/M22-2056","article-title":"Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American college of physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann. Intern. Med."},{"issue":"16","key":"10.1016\/j.jpsychires.2025.02.044_bib25","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease","volume":"78","author":"Richard","year":"2012","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.jpsychires.2025.02.044_bib26","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jpsychires.2010.03.006","article-title":"Response and remission criteria in major depression--a validation of current practice","volume":"44","author":"Riedel","year":"2010","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.jpsychires.2025.02.044_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/10401239409149001","article-title":"Diagnostic and statistical manual of mental disorders","volume":"6","author":"Runeson","year":"1994","journal-title":"Ann. Clin. Psychiatr. : official journal of the American Academy of Clinical Psychiatrists"},{"issue":"2","key":"10.1016\/j.jpsychires.2025.02.044_bib28","first-page":"40","article-title":"Updating the international classification of diseases and related health problems, tenth revision (ICD-10). Health information management","volume":"39","author":"Rust","year":"2010","journal-title":"journal of the Health Information Management Association of Australia"},{"issue":"11","key":"10.1016\/j.jpsychires.2025.02.044_bib29","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/14656566.2019.1612877","article-title":"Drug treatment strategies for depression in Parkinson disease","volume":"20","author":"Ryan","year":"2019","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.jpsychires.2025.02.044_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117109","article-title":"Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression","volume":"418","author":"Santos-Garcia","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jpsychires.2025.02.044_bib31","doi-asserted-by":"crossref","first-page":"h4718","DOI":"10.1136\/bmj.h4718","article-title":"How to read a funnel plot in a meta-analysis","volume":"351","author":"Sedgwick","year":"2015","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.jpsychires.2025.02.044_bib32","first-page":"4161","article-title":"The effects of mirtazapine on the depressive symptoms of Parkinson's disease","volume":"24","author":"Shen","year":"2013","journal-title":"Modern Diagnosis and Treatment"},{"issue":"5","key":"10.1016\/j.jpsychires.2025.02.044_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/mds.870110517","article-title":"Fluoxetine in Parkinson's disease","volume":"11","author":"Simons","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jpsychires.2025.02.044_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2377-10-49","article-title":"Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Skapinakis","year":"2010","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.02.044_bib35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaneurol.2014.2472","article-title":"Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability","volume":"72","author":"Smith","year":"2015","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.02.044_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1212\/WNL.43.1_Part_1.211","article-title":"Increase of Parkinson disability after fluoxetine medication","volume":"43","author":"Steur","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jpsychires.2025.02.044_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jad.2015.05.059","article-title":"Depression rating scales in Parkinson's disease: a critical review updating recent literature","volume":"184","author":"Torbey","year":"2015","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.jpsychires.2025.02.044_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178896","article-title":"Determinants of generic and specific health-related quality of life in patients with Parkinson's disease","volume":"12","author":"Tu","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jpsychires.2025.02.044_bib39","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40262-017-0614-5","article-title":"Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials","volume":"57","author":"van Dijkman","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.jpsychires.2025.02.044_bib40","first-page":"51","article-title":"The effects of escitalopram on the depressive symptoms of Parkinson's disease","volume":"21","author":"Wang","year":"2013","journal-title":"China Med. Eng."},{"issue":"5","key":"10.1016\/j.jpsychires.2025.02.044_bib41","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","article-title":"Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease","volume":"75","author":"Weintraub","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jpsychires.2025.02.044_bib42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/08039489850139049","article-title":"Depression in idiopathic Parkinson's disease treated with citalopram. A placebo-controlled trial","volume":"52","author":"Wermuth","year":"1998","journal-title":"Nord. J. Psychiatr."},{"issue":"5","key":"10.1016\/j.jpsychires.2025.02.044_bib43","first-page":"160","article-title":"The effects of fluoxetine on the depressive symptoms of Parkinson's disease","volume":"23","author":"Yu","year":"2011","journal-title":"Strait Pharmaceutical Journal"},{"issue":"8","key":"10.1016\/j.jpsychires.2025.02.044_bib44","first-page":"1043","article-title":"The effects of venlafaxin on the depressive symptoms and cognition function of Parkinson's disease","volume":"18","author":"Zhang","year":"2010","journal-title":"JOURNAL OF PRACTICAL CARDIOCEREBRAL PULMONARY VASCULOPATHY"},{"issue":"22","key":"10.1016\/j.jpsychires.2025.02.044_bib45","article-title":"Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis","volume":"96","author":"Zhuo","year":"2017","journal-title":"Medicine (Baltim.)"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625001232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625001232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:37:48Z","timestamp":1762209468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395625001232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"alternative-id":["S0022395625001232"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.02.044","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of newer-generation antidepressants medications in Parkinson's disease with depression - A meta-analysis of randomized controllde trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.02.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}